Keyword Search Year All2026202520242023202220212020201920182017 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update August 13, 2026 Read More Kyntra Bio to Report Second Quarter 2026 Financial Results August 6, 2026 Read More Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes June 11, 2026 Read More Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update May 11, 2026 Read More Kyntra Bio to Report First Quarter 2026 Financial Results May 4, 2026 Read More Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference April 8, 2026 Read More Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update March 16, 2026 Read More Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results March 9, 2026 Read More Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 February 23, 2026 Read More Kyntra Bio to Participate in Upcoming Investor Conferences February 17, 2026 Read More FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum January 7, 2026 Read More
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update August 13, 2026 Read More
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes June 11, 2026 Read More
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update May 11, 2026 Read More
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference April 8, 2026 Read More
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update March 16, 2026 Read More
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 February 23, 2026 Read More
